Skip to main content
PMC home page
Bulletin of the New York Academy of Medicine logoLink to Bulletin of the New York Academy of Medicine
. 1987 Apr;63(3):217–230.

Bacterial antibiotic resistance before and after clinical application in the United States.

A L Barry, R N Jones
PMCID: PMC1629239  PMID: 3111573

Full text

PDF
229

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson B. A., Lorian V. Antimicrobial agent susceptibility patterns of bacteria in hospitals from 1971 to 1982. J Clin Microbiol. 1984 Oct;20(4):791–796. doi: 10.1128/jcm.20.4.791-796.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barry A. L., Ayers L. W., Gavan T. L., Gerlach E. H., Jones R. N. In vitro activity of ticarcillin plus clavulanic acid against bacteria isolated in three centers. Eur J Clin Microbiol. 1984 Jun;3(3):203–206. doi: 10.1007/BF02014879. [DOI] [PubMed] [Google Scholar]
  3. Barry A. L., Jones R. N., Ayers L. W., Gavan T. L., Gerlach E. H. Activity of temocillin and ticarcillin against consecutively isolated Enterobacteriaceae in four medical centres. J Antimicrob Chemother. 1986 Apr;17(4):541–542. doi: 10.1093/jac/17.4.541. [DOI] [PubMed] [Google Scholar]
  4. Barry A. L., Jones R. N., Ayers L. W., Gavan T. L., Gerlach E. H., Sommers H. M. In vitro activity of apalcillin compared with those of piperacillin and carbenicillin against 6,797 bacterial isolates from four separate medical centers. Antimicrob Agents Chemother. 1984 May;25(5):669–671. doi: 10.1128/aac.25.5.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barry A. L., Jones R. N., Thornsberry C., Ayers L. W., Kundargi R. Imipenem (N-formimidoyl thienamycin): in vitro antimicrobial activity and beta-lactamase stability. Diagn Microbiol Infect Dis. 1985 Mar;3(2):93–104. doi: 10.1016/0732-8893(85)90017-3. [DOI] [PubMed] [Google Scholar]
  6. Barry A. L., Jones R. N., Thornsberry C., Fuchs P. C., Ayers L. W., Gavan T. L., Gerlach E. H., Sommers H. M. Cefpiramide: comparative in-vitro activity and beta-lactamase stability. J Antimicrob Chemother. 1985 Sep;16(3):315–325. doi: 10.1093/jac/16.3.315. [DOI] [PubMed] [Google Scholar]
  7. Barry A. L., Jones R. N., Thornsberry C., Fuchs P. C., Gerlach E. H., Sommers H. M. Ceftizoxime: collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, beta-lactamase stability, and inhibition. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):25–44. doi: 10.1093/jac/10.suppl_c.25. [DOI] [PubMed] [Google Scholar]
  8. Barry A. L., Jones R. N., Thornsberry C., Gavan T. L., Gerlach E. H., Sommer H. M. 3-0-demethyl fortimicin A: in vitro activity and interpretive zone standards for disk diffusion susceptibility tests. Eur J Clin Microbiol. 1984 Dec;3(6):531–537. doi: 10.1007/BF02013613. [DOI] [PubMed] [Google Scholar]
  9. Barry A. L., Thornsberry C., Jones R. N., Gavan T. L. Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests. Rev Infect Dis. 1985 Nov-Dec;7 (Suppl 4):S594–S604. doi: 10.1093/clinids/7.supplement_4.s594. [DOI] [PubMed] [Google Scholar]
  10. Findell C. M., Sherris J. C. Susceptibility of Enterobacter to cefamandole: evidence for a high mutation rate to resistance. Antimicrob Agents Chemother. 1976 Jun;9(6):970–974. doi: 10.1128/aac.9.6.970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fuchs P. C., Barry A. L., Thornsberry C., Jones R. N., Gavan T. L., Gerlach E. H., Sommers H. M. Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing. Antimicrob Agents Chemother. 1980 Jul;18(1):88–93. doi: 10.1128/aac.18.1.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fuchs P. C., Gavan T. L., Gerlach E. H., Jones R. N., Barry A. L., Thornsberry C. Ticarcillin: a collaborative in vitro comparison with carbenicillin against over 9,000 clinical bacterial isolates. Am J Med Sci. 1977 Nov-Dec;274(3):255–263. [PubMed] [Google Scholar]
  13. Fuchs P. C., Jones R. N., Thornsberry C., Barry A. L., Gerlach E. H., Sommers H. M. Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteria. Antimicrob Agents Chemother. 1981 Dec;20(6):747–759. doi: 10.1128/aac.20.6.747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jones R. N., Barry A. L., Fuchs P. C., Gavan T. L., Sommers H. M., Gerlach E. H. Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates. Antimicrob Agents Chemother. 1979 Dec;16(6):823–828. doi: 10.1128/aac.16.6.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jones R. N. Changing patterns of resistance to new beta-lactam antibiotics. In vitro efficacy of cefoperazone against bacterial pathogens. Am J Med. 1984 Jul 31;77(1B):29–34. doi: 10.1016/s0002-9343(84)80093-5. [DOI] [PubMed] [Google Scholar]
  16. Jones R. N., Fuchs P. C., Barry A. L., Gavan T. L., Sommers H. M., Gerlach E. H. Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin. Antimicrob Agents Chemother. 1980 Apr;17(4):743–749. doi: 10.1128/aac.17.4.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Jones R. N., Fuchs P. C. Comparison of in vitro antimicrobial activity of cefamandole and cefazolin with cephalothin against over 8,000 clinical bacterial isolates. Antimicrob Agents Chemother. 1976 Jun;9(6):1066–1069. doi: 10.1128/aac.9.6.1066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Jones R. N., Fuchs P. C., Gerlach E. H., Gavan T. L. Piperacillin and carbenicillin; a collaborative in vitro comparison against 10,838 clinical bacterial isolates. Cleve Clin Q. 1979 Summer;46(2):49–55. doi: 10.3949/ccjm.46.2.49. [DOI] [PubMed] [Google Scholar]
  19. Jones R. N., Fuchs P. C., Sommers H. M., Gavan T. L., Barry A. L., Gerlach E. H. Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin. Antimicrob Agents Chemother. 1980 Apr;17(4):750–756. doi: 10.1128/aac.17.4.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rotimi V. O., Turk D. C. Transferable multiple antibiotic resistance in Haemophilus influenzae. J Antimicrob Chemother. 1981 Sep;8(3):187–192. doi: 10.1093/jac/8.3.187. [DOI] [PubMed] [Google Scholar]
  21. Sanders C. C., Moellering R. C., Jr, Martin R. R., Perkins R. L., Strike D. G., Gootz T. D., Sanders W. E., Jr Resistance to cefamandole: a collaborative study of emerging clinical problems. J Infect Dis. 1982 Jan;145(1):118–125. doi: 10.1093/infdis/145.1.118. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES